Black Fungus–A Natural Aid to Cardiovascular and Digestive Wellness
On an episode of the 'Health 1+1' program, Zhang Weijun, fifth-generation successor of the renowned Taiwanese TCM family Huai Sheng Tang, shared a remarkable case. His father successfully treated a high school student who had suffered a heart attack using a combination of black fungus and traditional Chinese herbal medicine.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Epoch Times
2 hours ago
- Epoch Times
How to Manage Spondylolisthesis Without Surgery
Spondylolisthesis is a condition in which the vertebrae in the lower back become misaligned and displaced, causing them to slip out of position. It is most commonly seen in adults over 50 and is often associated with poor posture and prolonged periods of sitting. Without changes to daily habits, even surgical treatment may fail to deliver lasting results. In an episode of the 'Health 1+1' program, Zheng Yun-Long, an expert in spinal health and CEO of Taiwan's Body Learning Co., shared targeted exercises to help manage spondylolisthesis, along with practical guidance to prevent further spinal slippage. What Is Spondylolisthesis? The spine naturally follows an S-shaped curve. However, poor posture while standing, walking, or bending can cause the intervertebral discs—the soft cartilage between the vertebrae—to flatten or wear down. Over time, if the ligaments that connect and support the spine weaken, the vertebrae may begin to shift out of alignment, resulting in spondylolisthesis.
Yahoo
3 hours ago
- Yahoo
Why Doximity (DOCS) Stock Is Up Today
Shares of healthcare professional network Doximity (NYSE:DOCS) jumped 3% in the morning session after Evercore ISI analyst upgraded the stock, citing the company's growth potential. The investment firm raised its rating on the digital platform for medical professionals to "Outperform" from "In Line" and significantly increased its price target from $50 to $70 per share. Evercore ISI highlighted its belief that Doximity has provided conservative guidance for its 2026 fiscal year. The analyst firm projects strong growth in Doximity's pharmaceutical-related revenue, anticipating it will reach approximately $535 million in fiscal 2026. This optimism is partly fueled by continued spending related to GLP-1 drugs, a class of medications used to treat diabetes and obesity, which is expected to contribute around $60 million to revenue. After the initial pop the shares cooled down to $62.91, up 2.2% from previous close. Is now the time to buy Doximity? Access our full analysis report here, it's free. Doximity's shares are very volatile and have had 24 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. Doximity is up 17.5% since the beginning of the year, but at $62.91 per share, it is still trading 24.3% below its 52-week high of $83.14 from February 2025. Investors who bought $1,000 worth of Doximity's shares at the IPO in June 2021 would now be looking at an investment worth $1,187. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
5 hours ago
- Business Wire
Hims & Hers Announces Planned 2026 Expansion to Canada,
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS) the leading digital health and wellness platform, today announced its plans to bring its affordable, holistic weight loss program to Canada, timed with the anticipated first-ever availability of generic semaglutide anywhere in the world. This move follows the recent closing of the company's acquisition of ZAVA, the pioneering digital health platform in Europe. Almost two thirds of adults in Canada are overweight or living with obesity, yet access to proven treatments remains limited due to high costs and availability. With branded semaglutide often priced out of reach, the introduction of generics marks a pivotal moment for access to care. Hims & Hers plans to offer access to lower-cost treatment options through its digital platform, paired with 24/7 access to licensed providers and personalized, clinically backed care plans. In Canada, branded semaglutide with no surrounding clinical support currently costs more than C$200 a month. The price for generic semaglutide is expected to be available at a significant discount to the branded versions, with the prices expected to lower over time. 'Canada is a major opportunity to show what affordable, high-quality weight loss care can look like,' said Andrew Dudum, co-founder and CEO of Hims & Hers. 'As generic semaglutide becomes available for the first time globally, we're focused on making it truly accessible, by combining affordability with trusted, personalized care at scale.' This moment represents a significant opportunity for Hims & Hers to accelerate its mission of broadening access to healthcare. By pairing the arrival of generics with a platform designed to scale, affordability, and clinical integrity, the company is positioned to meet growing demand with a better model of care, one that gives the patient real choice and puts providers in the lead. "Our planned expansion into Canada proves our commitment to bringing modern, effective care to those who need it most," said David Meinertz, GM International at Hims & Hers. "Despite North America being the largest GLP-1 market, many still lack crucial access. Making affordable, holistic obesity treatment accessible has the potential to help strengthen the local healthcare system and unlock the potential for millions of Canadians to live healthier, more fulfilling lives.' With ZAVA now part of Hims & Hers, the company is scaling care across markets where its comprehensive offerings can meet consumer needs. The plans for Canada entry reflect continued progress on a clear growth roadmap, leveraging both organic growth and strategic investments to expand category leadership and global reach. About Hims & Hers Health, Inc. Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That's why we're building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit and About ZAVA ZAVA is a leading digital health platform in Europe, on a mission to make high-quality, dependable healthcare accessible and affordable. Serving more than 1.3 million active customers, ZAVA's in-house medical team delivered nearly 2.3 million consultations in 2024 across the UK, Germany, France and Ireland - putting compassionate, clinically-robust healthcare in people's hands 24/7. Rated 'outstanding' for leadership by the UK Care Quality Commission, ZAVA combines medical rigour with a friction-free digital experience. ZAVA's comprehensive service portfolio spans weight management, women's and men's health, sexual health, general medicine and skin & hair care - helping people tackle both everyday and sensitive conditions quickly, discreetly and safely. Cautionary Note Regarding Forward-Looking Statements Except for historical information, certain statements in this press release, including statements regarding the effects of entering into the acquisition described above, the timing and effects of our plans to expand into Canada, our expectations regarding our planned expansion into Canada, our expectations regarding integration of the ZAVA acquisition, our future performance, anticipated customer demand and the expected size of the total addressable Canadian market, the expected timing of availability of generic semaglutide, the ability to scale our business, the solutions accessible on our platform, our future operational capabilities, our long-term strategy, and the underlying assumptions with respect to the foregoing, are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, and are subject to risks, uncertainties and assumptions about Hims & Hers and its business. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties related to market conditions, our legal and regulatory environment, macroeconomic and geopolitical factors, and those factors described in the 'Risk Factors' section of each of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and any of our subsequent filings with the Securities and Exchange Commission (the 'Commission'). Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. These risks and others described in the 'Risk Factors' section of each of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and any of our subsequent filings with the Commission may not be exhaustive.
